Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA.HIVA
- Development stage
- Unknown
- Lead developer
- Medical Research Council
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA.HIVA is a viral vector-based vaccine candidate designed for the prevention of HIV-1 infection. Developed at the University of Oxford and sponsored by the Medical Research Council (MRC), the vaccine utilizes the Modified Vaccinia virus Ankara (MVA) platform, a highly attenuated strain of vaccinia virus. The vaccine construct expresses a consensus HIV-1 clade A immunogen (HIVA), which consists of a consensus clade A Gag p24/p17 sequence linked to a string of cytotoxic T-lymphocyte (CTL) epitopes. These epitopes are derived from the Gag, Pol, Env, and Nef proteins of HIV-1 clade A isolates common in East Africa. MVA.HIVA is engineered to induce robust T-cell mediated immune responses against HIV-1. It has been evaluated in several clinical trials, including the Phase I/II PedVacc 002 study, which assessed its safety and immunogenicity in healthy infants born to HIV-1-infected mothers in Kenya.
- Other names
- Modified Vaccinia virus Ankara-HIVAMVA-HIVA
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseNef (HIV-1 Nef)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)Gag (HIV-1 Gag polyprotein)
Beyond the preview
Go deeper on MVA.HIVA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA.HIVA.